TBF - he also linked retail investors to frustration with SP movement but he wanted to highlight the enthusiastic research unearthed by retail investors, taking the time not just to find relevant scientific papers, but also to translate them.
Interim Video now available - no Q&A07 Oct 2021 18:42
The Interim Report video is now available on the Synairgen website - but not the Q&A
In light of today's events, this is probably not particularly timely but nevertheless, I found it interesting to watch RM's video as I had not been able to watch it live. Picked up a few things not least RM saying near the beginning that "we are progressing well with the US govt who have included us in the Activ2 trial" before following this with caveats.
"Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation."
Just scrolled through today's comments on this thread. Apologies if this has already been mentioned.
On the Activ2, it does mention that certain key personnel in the supplying company will be updated with the results. (Sorry, cannot lay my hands on this actual quote atm though I did post it previously.)
Taken at face value, and with RM not overtly showing confidence that SNG001 will progress to A2P3, that would imply either or both: a) he has been cautioned against preempting the NIH decision either way b) the initial A2P2 results may have reflected our own home trial results and be inconclusive so the NIH is still deciding whether to pursue A2P3 or wait for results from Sprinter.
RE: Covid antiviral pill can halve risk of hospitalisation01 Oct 2021 18:17
Does this actually make sound financial sense?
$700 for mild to moderate cases, halving risk of hospitalisation to 7.5%. Isn't this still rather expensive? Even for USA? How much will the US health insurance companies payout for mild-moderate case, when most (85% by Merck's estimate) do not need hospitalisation. Yes, I know the US govt has made some sort of pre-order, but even so, how are they going to decide who gets Merck's pill? If just the moderate cases, what % of these will still end up in hospital as compared to the 7.5% when numbers are diluted with a combination of mild and moderate cases. I say clever PR machine.
RE: Covid antiviral pill can halve risk of hospitalisation01 Oct 2021 17:58
You might be on to something there, alkin. I noted this:
People living in the same household with someone who has tested positive for Covid-19, at least one related symptom and has not had signs or symptoms for more than five days will be eligible for the trial.
So have they included people who might not actually have had Covid?
A quick search on the BMJ brought up some old articles with seemingly negative bias towards interferon - I don't have membership so cannot confirm the detail. It did get me wondering how steep a hill Synairgen has had to climb to provide data, not only reverse the negative WHO trial, but also decades of antipathy towards interferon.
It gives even more weighting to the BoD's comments that 'data is king.'
I echo Saxondale, we need the results for SNG to get into the limelight. And a lot of work must be happening to prepare the ground to receive the data.